Biological therapy for psoriatic arthritis in clinical practice: Outcomes up to 2 years

17Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

Abstract

Objective. To evaluate the performance of biological drugs in psoriatic arthritis (PsA) in a routine care setting, using the Finnish national register of biological treatment (ROB-FIN). Methods. Patients with PsA who started therapy with infliximab or etanercept between June 2000 and February 2006 (n = 127) were followed for up to 24 months. Response was evaluated using American College of Rheumatology response criteria including individual measures. Results. Significantly diminished values for swollen and tender joints, patient's global and pain assessments, doctor's global assessment of disease activity, erythrocyte sedimentation rate, C-reactive protein, and Health Assessment Questionnaire score were observed within 3 months after commencement of both infliximab and etanercept. Values remained significantly lower throughout the 24 months of followup. ACR20 response at 3 months was 79% (n = 22/28) for infliximab and 76% (n = 34/45) for etanercept. The first biological drug was discontinued in 16% due to lack of effectiveness and in 6% due to adverse events. Conclusion. Anti-tumor necrosis factor-α therapy, often combined with conventional disease-modifying antirheumatic drugs, appeared to have limited toxicity and persistent effectiveness for up to 2 years in a cohort of Finnish patients with severe peripheral PsA. The Journal of Rheumatology Copyright © 2010. All rights reserved.

Cite

CITATION STYLE

APA

Virkki, L. M., Sumathikutty, B. C., Aarnio, M., Valleala, H., Heikkilä, R., Kauppi, M., … Nordström, D. C. (2010). Biological therapy for psoriatic arthritis in clinical practice: Outcomes up to 2 years. Journal of Rheumatology, 37(11), 2362–2368. https://doi.org/10.3899/jrheum.091477

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free